ROTAVIRUS (ROTATEQ) VACCINE

VACCINE USAGE: RotaTeq is a vaccine indicated for the prevention of rotavirus gastroenteritis caused by types G1, G2, G3, G4, and G9. RotaTeq is approved for use in infants 6 weeks to 32 weeks of age.

VACCINE DOSAGE: FOR ORAL USE ONLY. NOT FOR INJECTION.

The vaccination series consists of three ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.

VACCINE INGEDIENTS: sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, fetal bovine serum, vero cells [DNA from porcine circoviruses (PVC) 1 and 2 has been detected in RotaTeq. PCV-1 and PCV-2 is not known to cause disease in humans].

LIVE VIRUS VACCINE THAT HAS THE POTENTIAL TO SHED

ADVERSE VACCINE REACTIONS: bronchiolitis, gastroenteritis, pneumonia, fever, UTI, sudden infant death syndrome (SIDS), hematochezia, seizures, kawasaki disease, vomiting, diarrhea, irritability, anaphylactic reaction, intussusception (including death), urticaria, angioedema, “RotaTeq has not been evaluated for its carcinogenic or mutagenic potential or its potential to impair fertility.”